Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.3% (95% CI, 75.4%-87.9%), and a CBR of 71.5% (95% CI, 63.8%-78.4%). #kicsm #KCRS2025 | @kidneycan @AlbigesL cancernetwork.com/view/pembr…

Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works @FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !

🎉 Excited to share that @derosa_lisa will be the Keynote Speaker at 2025 IKCS: Europe! #IKCSEU25 Don't miss her talk on the kidney cancer #microbiome. Register with discount rates till 4/10! kidneycancer.swoogo.com/IKCS…

Day 1 @myESMO #Preceptorship in Metastatic #urothelial #RCC #cancer 62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC @myESMO #guidelines

In his Keynote Lecture at #ELCC25, @BenjaminBesseMD discusses when ‘less is more,’ describing different de-escalation strategies to balance the efficacy versus toxicity of #CancerTreatment, particularly #immunotherapy Read more in the #ESMODailyReporter🔗 ow.ly/sEeh50VqnHY

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at @myESMO and published in @NEJM

Please join @AlbigesL @g_develasco #JensBedkeMD & myself at #ESMO24 for a discussion of #kidneycancer that will span topics of #adjuvant & #metastatic dz tx. We have worked hard to incorporate discussion around data presented just a day earlier- incl perspectives on #TiNivo2, #SUNNIFORECAST, #LITESPARK005, as well as updates on #CM9ER, #CLEAR, #KN426 & other studies! See you Saturday evening at 6:30 pm!

#BreakingNews‌ Our 2023 IF is now 8.3 ! So proud of our amazing team @AlbigesL @UroDocAsh @Ric_Campi @Ecastromarcos @jteoh_hk @CaPsurvivorship @RenuEapen @GPloussard @CathyJPierce @EurUrolOncol

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by @VincentWenxinXu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with @AlbigesL spotifyanchor-web.app.link/e…

Circulating kidney injury molecule-1 may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma. #ASCO24 #kcsm @AlbigesL urologytimes.com/view/kim-1-…

Exciting preliminary data from Phase I/Ib study of HIF2α inhibitor DFF332 in pts w/ advanced ccRCC presented by my dear friend @montypal at #ASCO24: promising safety profile, indications of clinical activity, and dose-proportional modulation of EPO.
 @ASCO @AlbigesL @OncoAlert @DanaFarber_GU

Top 5 Must See Kidney and Bladder Data @montypal #ASCO24 @ASCO @AlbigesL @brian_rini @motzermd @shilpaonc @CityofHope_GU @cityofhope Click Here for the Data Links: oncologytube.com/monty-pal-m…

Don't miss tomorrow's Rapid Oral Abstract Session - Friday 8:30 @Montypal will present the Preliminary results of P1 study monotherapy of DFF332: promising safety profile & have been indications of clinical activity @ASCO #ASCO24 @AlbigesL 👉meetings.asco.org/abstracts-…

Renal cancer highlights #ASCO24 KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) ⬆️ in kidney injury and is immune suppressive(Treg), Already used for nephrotox. @motzermd presented compelling data form adjuvant ipi/nivo #AACR24. A 2nd +ve study would be meaningful?

Updated 📢#RenalCellCarcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data for first-line metastatic trials as well as sequencing strategies & new agents such as belzutifan. ow.ly/nZA050RP77l #kcsm @silke_gillessen @tompowles1 @evacomperat @AlbigesL @ViktorGruenwald @ravikanesvaran @DrRanaMcKay @g_procopio_ @schmidingerRCC @g_develasco

#ASCO24 abstracts titles are out!!!! brnw.ch/21wJ8kD My top 5 communications in Kidney & Bladder based on the titles: 1. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. @motzermd 2. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). @shilpaonc 3. Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. @DanielPetrylak 4. Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. @AlbigesL 5. Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma. @montypal But there are many other updates of combos we use for metastatic tumors!!! Can't wait to see you all!!! Congrats to the presenters!!! @DrChoueiri @MattGalsky @tompowles1 @brian_rini and many others!!! @ASCO @OncoAlert @DrYukselUrun

Still time to apply 👉 #ESMOPreceptorship on Metastatic #BladderCancer & #KidneyCancer: molecular pathology & diagnosis as contributing factors to heterogeneity, assessment & multidisciplinary tx, advances in tx & novel targets 🔗 ow.ly/FZeH50QBJBl #blcsm #kcsm @AlbigesL

Proud of @GustaveRoussy GU group celebrating 20th anniversary #GU24 🎂 Thrilled to contribute to 20years of advances in GU cancers care ! Missing @PBlanchardMD @AlbertoBossial @drcmassard

The #MCCRWorkshop enables peer #mentoring and #CareerDevelopment for early-career #oncology professionals. Apply now to gain access to mentors and develop protocols ready for submission. ⏲️ Deadline: 1 February 2024. ow.ly/m7TG50QtYnF @EORTC @AACR #CancerResearch

Listening to "December 2023 – Eur Urol Oncology highlights" at buzzsprout.com/2220728/14276… @EurUrolOncol @Uroweb @UroDocAsh @Ric_Campi @CathyJPierce @Ecastromarcos @CaPsurvivorship @GPloussard @jteoh_hk @AlbigesL @declangmurphy